SCHEMBL31673722

SCHEMBL31673722

Cc1ccc2c(c1)N(CCCCN1CCC(N3CCCC3)CC1)c1ccccc1S2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 8/20 0.68
▸ FPR2 P25090 5/20 0.55
▸ DRD3 P35462 7/20 0.52
▸ DRD2 P14416 7/20 0.52
▸ HRH1 P35367 7/20 0.52
▸ SLC6A2 P23975 6/20 0.52
▸ SLC6A4 P31645 6/20 0.52
▸ HTR1A P08908 5/20 0.52
▸ ADRA2A P08913 5/20 0.52
▸ CHRM1 P11229 5/20 0.52
▸ DRD1 P21728 5/20 0.52
▸ ADRA1A P35348 5/20 0.52
▸ SLC6A3 Q01959 5/20 0.52
▸ KCNH2 Q12809 5/20 0.52
▸ ADRA2C P18825 5/20 0.52
▸ HTR2A P28223 5/20 0.52
▸ CHRM2 P08172 4/20 0.52
▸ CYP2D6 P10635 4/20 0.52
▸ ADRA2B P18089 4/20 0.52
▸ HTR2C P28335 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20412134 1.00 KDM1A (0.68) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20412149 0.99 KDM1A (0.70) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20425968 0.98 KDM1A (0.68) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20425971 0.97 KDM1A (0.70) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20412079 0.94 KDM1A (0.68) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL31673733 0.94 KDM1A (0.68) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20412075 0.93 KDM1A (0.70) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20412098 0.92 KDM1A (0.68) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL31673756 0.92 KDM1A (0.68) KDM1AFPR2DRD3DRD2HRH1
SCHEMBL20425964 0.91 KDM1A (0.63) KDM1AFPR2DRD3DRD2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255879-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-08-14 — — US claimed
US-20250255879-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-08-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250255879-A1 PHARMACEUTICAL COMPOSITION FOR ANTI-CANCER COMPRISING NUPR1 ISOFORM A INHIBITOR NUP205, NUP188, NUP50 KDM1A 1562/4885FPR2 4728/4885DRD3 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback